Source: http://www.google.com/patents/US8163726?dq=6519629
Timestamp: 2016-06-28 09:48:28
Document Index: 309485572

Matched Legal Cases: ['Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 03', 'Application No. 03', 'Application No. 2004']

Patent US8163726 - Method of inhibiting choroidal neovascularization - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening...http://www.google.com/patents/US8163726?utm_source=gb-gplus-sharePatent US8163726 - Method of inhibiting choroidal neovascularizationAdvanced Patent SearchPublication numberUS8163726 B2Publication typeGrantApplication numberUS 10/665,203Publication dateApr 24, 2012Filing dateSep 18, 2003Priority dateSep 18, 2002Fee statusPaidAlso published asCA2498191A1, CA2498191C, EP1539157A2, EP1539157A4, EP1539157B1, EP2514420A2, EP2514420A3, EP2514420B1, US8618088, US20050187241, US20090036479, US20120190705, WO2004027027A2, WO2004027027A3Publication number10665203, 665203, US 8163726 B2, US 8163726B2, US-B2-8163726, US8163726 B2, US8163726B2InventorsRong Wen, Zhijun Luo, Alan M. LatiesOriginal AssigneeUniversity Of PennsylvaniaExport CitationBiBTeX, EndNote, RefManPatent Citations (87), Non-Patent Citations (33), Referenced by (1), Classifications (11), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetMethod of inhibiting choroidal neovascularization
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5011844Aug 25, 1989Apr 30, 1991Sandoz Ltd.Substituted 4-azatricyclo(22.3.1.04,9)octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing themUS5078999Feb 22, 1991Jan 7, 1992American Home Products CorporationMethod of treating systemic lupus erythematosusUS5100899Jun 6, 1989Mar 31, 1992Roy CalneMethods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereofUS5189042Aug 22, 1991Feb 23, 1993Merck & Co. Inc.Fluoromacrolides having immunosuppressive activityUS5192773Jul 2, 1990Mar 9, 1993Vertex Pharmaceuticals, Inc.Immunosuppressive compoundsUS5258389Nov 9, 1992Nov 2, 1993Merck & Co., Inc.O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivativesUS5368865Jul 27, 1993Nov 29, 1994Fujisawa Pharmaceutical Co., Ltd.Suspendible composition and process for preparing the sameUS5378475Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devicesUS5387589 *Nov 17, 1992Feb 7, 1995University Of Louisville Research Foundation, Inc.Method of treating ocular inflammationUS5457111Nov 9, 1993Oct 10, 1995Abbott LaboratoriesMacrocyclic immunomodulatorsUS5514686Apr 24, 1992May 7, 1996Fujisawa Pharmaceutical Co., Ltd.Use of macrolide compounds for eye diseasesUS5516770Sep 22, 1994May 14, 1996American Home Products CorporationRapamycin formulation for IV injectionUS5527907Oct 26, 1994Jun 18, 1996Abbott LaboratoriesMacrolide immunomodulatorsUS5530006Mar 7, 1994Jun 25, 1996American Home Products CorporationRapamycin formulation for IV injectionUS5532248May 12, 1995Jul 2, 1996Merck Co., Inc.O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activityUS5559121May 23, 1995Sep 24, 1996American Home Products CorporationRapamycin formulations for oral administrationUS5601844Nov 11, 1993Feb 11, 1997Fujisawa Pharmaceutical Co., Ltd.Sustained release medicinal preparationUS5616588Sep 12, 1994Apr 1, 1997American Home Products CorporationRapamycin formulation for IV injectionUS5621108Dec 5, 1994Apr 15, 1997Trustees Of The University Of PennsylvaniaProcesses and intermediates for preparing macrocyclesUS5672605Apr 19, 1995Sep 30, 1997Abbott LaboratoriesMacrolide immunomodulatorsUS5773019Sep 27, 1995Jun 30, 1998The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the bodyUS5800807 *Jan 29, 1997Sep 1, 1998Bausch & Lomb IncorporatedOphthalmic compositions including glycerin and propylene glycolUS5883082Nov 23, 1994Mar 16, 1999Isis Pharmaceuticals, Inc.Compositions and methods for preventing and treating allograft rejectionUS6015815Sep 24, 1998Jan 18, 2000Abbott LaboratoriesTetrazole-containing rapamycin analogs with shortened half-livesUS6254860Apr 13, 1999Jul 3, 2001Allergan Sales, Inc.Ocular treatment using cyclosporin-A derivativesUS6329386Nov 2, 1999Dec 11, 2001Abbott LaboratoriesTetrazole-containing rapamycin analogs with shortened half-livesUS6376517Aug 14, 1998Apr 23, 2002Gpi Nil Holdings, Inc.Pipecolic acid derivatives for vision and memory disordersUS6387918Feb 18, 1998May 14, 2002Fujisawa Pharmaceutical Co., Ltd.Pharmaceutical compositionUS6399629Jul 1, 1998Jun 4, 2002Microcide Pharmaceuticals, Inc.Efflux pump inhibitorsUS6440990May 23, 1997Aug 27, 2002Novartis AgO-alkylated rapamycin derivatives and their use, particularly as immunosuppressantsUS6482802May 11, 1999Nov 19, 2002Endowment For Research In Human Biology, Inc.Use of neomycin for treating angiogenesis-related diseasesUS6534693Jan 31, 2001Mar 18, 2003Afmedica, Inc.Surgically implanted devices having reduced scar tissue formationUS6576224May 25, 2000Jun 10, 2003Sinuspharma, Inc.Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitisUS6632836Oct 21, 1999Oct 14, 2003Merck & Co., Inc.Carbocyclic potassium channel inhibitorsUS6699493Nov 28, 2001Mar 2, 2004Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use thereforUS6713081Mar 15, 2001Mar 30, 2004The United States Of America As Represented By The Department Of Health And Human ServicesOcular therapeutic agent delivery devices and methods for making and using such devicesUS6812220Aug 28, 2002Nov 2, 2004University Of British ColumbiaPharmaceutical compositions and methods relating to fucansUS6872383Jan 30, 2003Mar 29, 2005Sucampo AgUse of macrolide compounds for the treatment of dry eyeUS6890546Sep 10, 2001May 10, 2005Abbott LaboratoriesMedical devices containing rapamycin analogsUS20020123505Sep 10, 2001Sep 5, 2002Mollison Karl W.Medical devices containing rapamycin analogsUS20030018044Sep 19, 2002Jan 23, 2003Peyman Gholam A.Treatment of ocular diseaseUS20030027744Apr 18, 2002Feb 6, 2003Dana M. RezaUse of a CD40:CD154 binding interruptor to treat immunological complications of the eyeUS20030031631Aug 28, 2002Feb 13, 2003Osbakken Robert S.Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitisUS20030069560May 2, 2002Apr 10, 2003Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereofUS20030077297Feb 11, 2002Apr 24, 2003Feng-Jing ChenPharmaceutical formulations and systems for improved absorption and multistage release of active agentsUS20030190286Aug 29, 2002Oct 9, 2003Dugger Harry A.Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthmaUS20040018228May 7, 2003Jan 29, 2004Afmedica, Inc.Compositions and methods for reducing scar tissue formationUS20040057958May 19, 2003Mar 25, 2004Waggoner David W.Immunogenicity-enhancing carriers and compositions thereof and methods of using the sameUS20040092435Nov 7, 2002May 13, 2004Peyman Gholam A.Treatment of ocular diseaseUS20040167152Jul 25, 2003Aug 26, 2004WyethParenteral formulationsUS20040234611Sep 13, 2002Nov 25, 2004Marklus AhlheimOphthalmic deport formulations for periocular or subconjunctival administrationUS20050025810Jul 31, 2003Feb 3, 2005Gholam PeymanTreatment of ocular diseaseUS20050048123Jun 25, 2004Mar 3, 2005Control Delivery System, Inc.In situ gelling drug delivery systemUS20050123605Oct 7, 2004Jun 9, 2005Angiotech Pharmaceuticals, Inc.Anti-angiogenic compositions and methods of useEP0041745A1May 12, 1981Dec 16, 1981SADEPAN CHIMICA S.p.A.Urea-formaldehyde resin based adhesive containing calcium and/or ammonium ligninsulphonate as additive, a urea-formaldehyde resin modified with calcium and/or ammonium ligninsulphonate, and methods for the production thereof, for preparing agglomerated wood panelsEP0041795B1May 27, 1981Jan 16, 1985Ayerst, Mckenna And Harrison Inc.Injectable composition of rapamycinJP2002522485A * Title not availableWO1993019763A1Mar 29, 1993Oct 14, 1993American Home Products CorporationRapamycin formulation for iv injectionWO1994021642A1Mar 11, 1994Sep 29, 1994Abbott LaboratoriesMacrocyclic amide and urea immunomodulatorsWO1996041865A1Jun 7, 1996Dec 27, 1996Ariad Gene Therapeutics, Inc.Rapamcycin-based regulation of biological eventsWO1997010806A1Sep 18, 1996Mar 27, 1997Fujisawa Pharmaceutical Co., Ltd.Aerosol compositionsWO1997016068A1Oct 28, 1996May 9, 1997Merck & Co., Inc.Triterpene derivatives with immunosuppressant activityWO1999020261A2Oct 22, 1998Apr 29, 1999Jens PonikauUse of antigunal agents for the topial treatment of fungus-induced mucositisWO1999022722A2Oct 30, 1998May 14, 1999Abbott LaboratoriesUse of macrolides for the treatment of cancer and macular degenerationWO1999034830A1Dec 17, 1998Jul 15, 1999Galena, A.S.Topical ophthalmic preparations containing immunosuppressive agentsWO1999037667A1Jan 22, 1999Jul 29, 1999Microcide Pharmaceuticals, Inc.Efflux pump inhibitorsWO1999058126A1May 11, 1999Nov 18, 1999The Endowment For Research In Human Biology, Inc.Use of neomycin for treating angiogenesis-related diseasesWO2000009109A2Aug 12, 1999Feb 24, 2000Gpi Nil Holdings, Inc.Pipecolic acid derivatives for vision and memory disordersWO2000028945A2Oct 12, 1999May 25, 2000Ortho-Mcneil Pharmaceutical, Inc.Anticonvulsant derivatives useful in treating post traumatic stress disorderWO2000038703A1Dec 20, 1999Jul 6, 2000R-Tech Ueno, Ltd.Agent for treating visual cell function disorderWO2000040089A1Jan 5, 2000Jul 13, 2000Massachusetts Eye And Ear InfirmaryTargeted transscleral controlled release drug delivery to the retina and choroidWO2001030386A1Oct 19, 2000May 3, 2001Biogen, Inc.Use of a cd40:cd154 binding interruptor to treat immunological complications of the eyeWO2001042219A2Dec 7, 2000Jun 14, 2001Inotek CorporationNovel substituted phenanthridinones and methods of use thereofWO2001047495A1Dec 1, 2000Jul 5, 2001Pfizer Products Inc.Pharmaceutical compositions providing enhanced drug concentrationsWO2002028387A1Oct 3, 2001Apr 11, 2002Oncopharmaceutical, Inc.Inhibitors of angiogenesis and tumor growth for local and systemic administrationWO2002062335A2Jan 16, 2002Aug 15, 2002Vascular Therapies, LlcImplantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular graftsWO2002074196A1Mar 14, 2002Sep 26, 2002The United States of America, represented by The Secretary, Department of Health & Human ServicesOcular therapeutic agent delivery devices and methods for making and using such devicesWO2003068186A1Feb 11, 2003Aug 21, 2003Lipocine, Inc.Pharmaceutical formulations and systems for improved absorption and multistage release of active agentsWO2003074027A2Feb 28, 2003Sep 12, 2003Novagali Pharma SaSelf emulsifying drug delivery systems for poorly soluble drugsWO2003074029A1Mar 7, 2003Sep 12, 2003Vectura LimitedFast melt multiparticulate formulations for oral deliveryWO2003090684A2Apr 24, 2003Nov 6, 2003Sun Biomedical, Ltd.Polymer compositions containing a macrocyclic triene compoundWO2004019904A1Aug 27, 2003Mar 11, 2004Novadel Pharma Inc.Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthmaWO2004027027A2Sep 18, 2003Apr 1, 2004Trustees Of The University Of PennsylvaniaMethod of inhibiting choroidal neovascularizationWO2004028477A2Sep 29, 2003Apr 8, 2004Surmodics, Inc.Methods for treatment and/or prevention of retinal diseaseWO2004043480A2Sep 10, 2003May 27, 2004Peyman Gholam AIntraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosaWO2004074445A2Feb 17, 2004Sep 2, 2004Cold Spring Harbor LaboratoryModel for studying the role of genes in tumor resistance to chemotherapyWO2005051452A2Nov 22, 2004Jun 9, 2005Angiotech International AgPolymer compositions and methods for their use* Cited by examinerNon-Patent CitationsReference1"Study of possible anticancer drug reveals new mechanism of gene regulation." NewsRx. Jan. 14, 2003.2Akselband, et al. "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts" Transplantation Proceedings, vol. 23, No. 6. Dec. 1991:p. 2833-2836.3Auricchio, et al. "Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye" Molecular Therapy, Jul. 1, 2002, p. 238-242.4Bainbridge, et al. "Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization." Gene Therapy. 2003:p. 1049-1054.5Canadian Intellectual Property Office-Office Action, Application No. 2,498,191, dated Mar. 15, 2011.6Canadian Intellectual Property Office—Office Action, Application No. 2,498,191, dated Mar. 15, 2011.7Canadian Intellectual Property Office-Office Action, Application No. 2,498,191, dated May 6, 2010.8Canadian Intellectual Property Office—Office Action, Application No. 2,498,191, dated May 6, 2010.9EPO Supplementary Partial European Search Report, for EP Application No. EP 03 75 4653; dated Jul. 18, 2008.10EPO-Invitation to Correct Deficiencies, Application No. 03 754 653.8-1216, dated Jun. 25, 2010.11EPO—Invitation to Correct Deficiencies, Application No. 03 754 653.8-1216, dated Jun. 25, 2010.12Guba, et al. "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor." Nature Medicine. vol. 8. No. 2. Feb. 2002. p. 128-135.13Guba, et al. "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis" Chirurgisches Forum 2001. May 1, 2001: p. 37-39.14Hackstein et al., "Rapamycin inhibits macropinocytosis and mannose receptor-mediated . . .", Blood; vol. 100 No. 3 (1084-1087), Aug. 2002.15Hackstein et al., "Rapamycin inhibits macropinocytosis and mannose receptor—mediated . . .", Blood; vol. 100 No. 3 (1084-1087), Aug. 2002.16 *Hikita, Naofumi, Journal of the Kurume Medical Association, Jan. 1994, vol. 57, No. 1, pp. 176-189, Japan (in Japanese).17Humar, et al. "Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling." The FASEB Journal. vol. 16. Jun. 2002: p. 771-780.18 *Japanese Patent Office Action, Patent Application No. 2004-537893, Mailing Date, Sep. 29, 2009 (English Translation).19 *Kimura, Hideya, Angiogenesis Inhibitors, Atarashii Ganka (New Ophthalmology), Jul. 30, 2001, vol. 18, No. 7, pp. 867-870, Japan (in Japanese).20Kuroki, et al. "Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice." ARVO 2003 Abstract No. 573. May 4, 2003.21Marsland. "The macrolide immunosuppressants in dermatology: mechanisms of action." Eur. J Dermatol. Nov.-Dec. 2002. p. 618-22.22Olsen, et al. "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization," Arch. Ophthalmol, vol. 112, pp. 1471-1475, Nov. 1994.23Renau, et al. "Addressing the Stability of C-Capped Dipeptide Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic & Med. Chem. Letters. (2001) 11:663-667.24Renau, et al., "Conformationally-Restricted Analogues of Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic& Med. Chem. Letters. (2003) 13:2755-2758.25Rivera et al., "Long-term regulated expression of growth hormone in mice after intramuscular gene transfer," PNAS; vol. 96: 8657-8662, Jul. 1999.26Shen, et al. "Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinat Adenovirus-Mediated Transgene Expression in the Retina." Arch Ophthalol. Jul. 2001. vol. 119. p. 1033-1043.27Simamora, P. et al., "Solubilization of Rapamycin," Int. J. Pharm. 213:25-29, Feb. 1, 2001.28Sloper C. Myra L. et al., Tacrolimus (FK506) in the Treatment of Posterior Uveitis Refractory to Cyclosporine, Ophthalmology, Apr. 1999, pp. 723-728, vol. 106, No. 4.29Stepkowski et al., "Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat," Transplantation, vol. 51:22-26, Jan. 1991.30Treins, et al. "Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway." Journal of Biological Chemistry, Aug. 2, 2002. vol. 277, No. 31 p. 27975-27981.31U.S. Appl. No. 60/503,840, Cooper et al.32Wen, et al. "Rapamycin Inhibits Choroidal Neovascularization" ARVO 2003. Abstract No. 3928 May 7, 2003.33 *Zubilewicz, A., et al., Two Distinct Signalling Pathways are Involved in FGF2-Stimulated Proliferation of Choriocapillary Endothelial Cells: A Comparative Study With VEGF, Mar. 22, 2001, vol. 20, No. 12, pp. 1403-1413 (in English).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8912215Dec 13, 2011Dec 16, 2014Everon Biosciences, Inc.Rapamycin compositionClassifications U.S. Classification514/185, 514/912International ClassificationC12N, A61K31/445, A61K31/555, A61K31/4745Cooperative ClassificationY10S514/912, A61K31/436, A61K31/445European ClassificationA61K31/445, A61K31/436Legal EventsDateCodeEventDescriptionMar 14, 2005ASAssignmentOwner name: UNIVERSITY OF PENNSYLVANIA, PENNSYLVANIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEN, RONG;LUO, ZHIJUN;LATIES, ALAN M.;REEL/FRAME:015900/0032Effective date: 20050104Sep 11, 2012CCCertificate of correctionOct 7, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services